文献速递骨显像与常规 SPECT肿瘤 PET/CT

镓-67柠檬酸盐SPECT/CT与氟-18 FDG-PET/CT评估坏死性外耳道炎治疗反应

[67Ga]Ga-citrate SPECT/CT and [18F]FDG-PET/CT for evaluating therapeutic response in necrotizing otitis externa.
PubMed 文献 · EJNMMI Res · 2026-04-25

95次扫描的定性评估显示镓-67 SPECT/CT观察者间一致性轻微(kappa=0.167),FDG-PET/CT一致性中等(kappa=0.400);复发见于影像完全缓解和未完全缓解的患者。半定量分析中,镓-67 SPECT/CT的countsmax比值从1.93降至1.35,但countsmean比值从1.56升至1.73;FDG-PET/CT的SULmax和SULpeak比值均下降50%,多数病例MTV下降。

要点

  • 镓-67 SPECT/CT定性评估观察者间一致性轻微(kappa=0.167),FDG-PET/CT为中等(kappa=0.400)。
  • 影像完全缓解与否均可见复发,提示不能仅凭影像缓解判断停药。
  • FDG-PET/CT的MTV可能有助于量化疾病过程中的代谢变化。

核心结论

  • 镓-67 SPECT/CT和FDG-PET/CT半定量测量在坏死性外耳道炎中显示明显变异。
  • MTV可能是量化FDG-PET/CT结果的有用参数。
  • FDG-PET/CT视觉评估联合MTV似乎最有效,但观察者间变异强调标准化协议的必要性。

研究设计与样本

  • 共评估95次扫描,包括镓-67 SPECT/CT和/或FDG-PET/CT,评估治疗期间影像疾病活动度及停药时活动与疾病控制的关系。
  • 同时评估观察者间变异。

主要发现

  • 3例患者复发。
  • 镓-67 SPECT/CT定性评估观察者间一致性轻微(kappa=0.167),FDG-PET/CT一致性中等(kappa=0.400)。
  • 复发见于影像完全缓解和未完全缓解的患者。
  • 镓-67 SPECT/CT半定量:countsmax比值从1.93降至1.35,countsmean比值从1.56升至1.73(基线至治疗结束)。
  • FDG-PET/CT半定量:SULmax和SULpeak比值均下降50%,多数病例MTV下降。

关键数值与推荐

  • 镓-67 SPECT/CT定性评估观察者间kappa=0.167。
  • FDG-PET/CT定性评估观察者间kappa=0.400。
  • 镓-67 SPECT/CT countsmax比值从1.93降至1.35,countsmean比值从1.56升至1.73。
  • FDG-PET/CT SULmax和SULpeak比值均下降50%。

临床怎么用

  • FDG-PET/CT视觉评估联合MTV可能有助于评估坏死性外耳道炎治疗反应。
  • 影像完全缓解不能单独作为安全停用抗生素的依据,需结合临床。
  • 临床实践中应采用标准化评估协议以提高观察者间一致性。

局限性

  • 观察者间一致性仅为轻微至中等。
  • 复发患者数量少(3例),限制影像表现与复发关系的分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Necrotizing otitis externa (NOE) is a rare but severe infection of the external ear canal that can progress to osteomyelitis of the temporal bone, often caused by Pseudomonas aeruginosa. Effective management requires prolonged systemic antibiotic therapy, as premature termination increases the risk of relapse. There is ongoing debate regarding the optimal duration of antibiotic treatment and the criteria for discontinuation. Functional imaging techniques, such as [67Ga]Gallium citrate SPECT/CT and [18F]FDG-PET/CT, have shown promise in assessing disease activity, but their roles in therapy evaluation remain underexplored. In this study, we describe the radiological disease activity during treatment and we relate activity at cessation of treatment to disease control in patients scanned with [67 Ga]Ga-citrate SPECT/CT and/or [18F]FDG-PET/CT. Secondly, inter-rater variability is assessed. RESULTS: Twenty patients with NOE, with a median duration of intravenous treatment of six months (range 1–24 months) were included. Relapse occurred in 3 patients. Qualitative assessment of 95 scans showed slight inter-rater agreement for [67Ga]Ga-citrate SPECT/CT (kappa = 0.167) and fair agreement for [18F]FDG-PET/CT (kappa = 0.400). Relapse was seen in patients both with and without complete resolution on imaging. In the semi-quantitative assessment, [67Ga]Ga-citrate SPECT/CT showed a decrease in countsmax ratio (1.93 to 1.35), but an increase in countsmean ratio (1.56 to 1.73) between baseline and end of treatment. [18F]FDG-PET/CT showed a 50% reduction in both maximal standardized uptake value, corrected for lean body mass (SULmax) and peak standardized uptake value, corrected for lean body mass (SULpeak) ratios and also a decrease in metabolic tumor volume (MTV) in most cases. CONCLUSIONS: Semi-quantitative measurements on [67Ga]Ga-citrate SPECT/CTs and [18F]FDG-PET/CTs demonstrated notable variation in NOE. However, our findings suggest that MTV might be a useful parameter in quantifying the [18F]FDG-PET/CT result during the course of disease. Although [18F]FDG-PET/CT with visual evaluation, potentially alongside MTV, appears to be the most effective, the inter-observer variability emphasizes the necessity for standardized protocols to improve consistency and reliability in clinical practice and to guide clinical decision-making.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Vosbeek EGM, Straatman LV, de Keizer B, et al. [67Ga]Ga-citrate SPECT/CT and [18F]FDG-PET/CT for evaluating therapeutic response in necrotizing otitis externa. EJNMMI Res. 2026. PMID: 42033566. doi:10.1186/s13550-026-01439-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。